np'29 - Most of us are wondering what's behind the recent price/volume action. It may be only market players manipulating a biotech with news hints. Or it may presage something fundamental. Your guess is one possibility. Another is the likely approval of Amgen's T-vec. IF our patent portfolio does prove to cover modified HSV oncotherapy it would be worth several dollars a share. And that T-vec decision is coming up - Apr for the advisory committee's reco. Oct for final decision. At this point, it's anybody's guess what's driving the recent action.
this is due out march 2015
Phase 2 Study of REOLYSINÂ® in Combination With
Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR
and if it is what is the implications
I suspect that ONCY will issue a press release on Monday to announce this 3rd approved FDA Orphan Drug Designation, this time in Fallopian Tube Cancers.
According to wikipedia "Demographic distribution is similar to ovarian cancer, and the highest incidence was found in white, non-Hispanic women and women aged 60–79. However, recent evidence suggests tubal cancer to be much more frequent . Evidence is accumulating that individuals with mutations of BRCA1 and BRCA2 are at higher risks for the development of PFTC."
The incidence of fallopian tube cancer is often underestimated due to its co-existence with ovarian masses, and frequently Fallopian tube carcinoma is misdiagnosed as a metastasis from a primary ovarian carcinoma. Cancers that metastasise to fallopian tubes include ovarian, endometrial, gastrointestinal tract and breast.
Kenny - this is the message that prompted my confirmatory response 20 minutes later.
I have tried 4 times to respond and yahoo has removed my response each time. But read the message board from 3:00 p.m. yesterday to the point of where I posted to understand what prompted my post.
Bailey, you are great at finding things, and we (I) appreciate your efforts, but I wonder.... Perhaps Brad would like to release info on his time frame, not someone else's? Just a thought, and what I am thinking is he would like to let a couple of things stack up so he can release several things at once, perhaps sparking a much bigger buying spree, getting us well over a buck..... yea, I don't know but are you actually partially defeating the goal????
Sentiment: Strong Buy
It's a gamble. The best trial results this far have resulted in "interesting" results. Other words, trials show perhaps a subset of the population respond to treatment....but really, this has been one disappointment event after another. To date, no phase 3 trials have met their primary objective. The pro ONcY posters on this message board have demonstrated a complete ignorance of facts. It's entertaining, but sad. That being said, im holdong out for a lucky buy out or a surprise news release with good clinical trial data.
Where do u live? From Alaska, CO,or Washington Have you had Marihuana today
That is because people are expecting a pop when they announce Orphan Drug Designation for Fallopian maybe on Monday. I am shocked was not announced today
yeah I tend to agree with that sentiment. I bought it at .51 couple weeks ago on first news. don't have a huge position so I think I may just hold. still think there is great potential but not going to do much short term
ONCY has been granted 3 FDA Orphan Drug Status Designations in the past 2 weeks - has at least 2 more to be granted by the EMA in the near term - and the potential of multiple partnership announcements - and the possible announcements of at least 4 Phase III clinical trials over the near-intermediate time-frame should be a enough of an answer right now for anyone looking to go long this stock.
What do you think of the long term? If it goes up temporarily that's nice but have you considering holding any?
Don't suppose you have a link or an explanation of how you know this or where to find it? Not doubting you, just curious.